Resolor (Prucalopride) safe and effective in Severe Chronic Constipation

Data presented at the United European Gastroenterology Week show Movetis’ Prucalopride to demonstrate efficacy and safety in patients with chronic constipation.

Aryx announce favorable QT results with 5HT4 agonist ATI-7505

ARYx Therapeutics have announced that its 5HT4 agonist ATI-7505 had demonstrated a favorable cardiotoxicity profile in a thorough QT study.

Procter & Gamble Ends Collaboration on ATI-7505

Procter & Gamble has ended its collaboration with ARYx Therapeutics for development and commercialization of 5-HT4 agonist ATI-7505 for chronic constipation and functional dyspepsia.

ARYx 5HT4 agonist ATI-7505 shows favorable QT profile

ARYx Therapeutic’s 5HT4 agonist ATI-7505 has shown a favorable QT profile. The drug is in Phase II trials for chronic constipation and functional dyspepsia.

Epix initiate second Phase IIb trial of 5HT4 agonist PRX-03140 for Alzheimer’s disease

EPIX Pharmaceuticals have initiated a second Phase IIb trial of its 5-HT4 agonist PRX03140 in Alzheimers disease. The trial will evaluate PRX-03140 when adminstered as a monotherapy and in combination with donepezil

Phase III data on Resolor (prucalopride) published in NEJM

Phase III data that detail the efficacy an safety of Resolor (prucalopride) in chronic constipation have been  published in The New England Journal of Medicine (NEJM).

Movetis file Resolor MAA for chronic constipation

Movetis have filed a Marketing Authorization Application (MAA) submission for Resolor (prucalopride) as a treatment for chronic constipation in adults in whom laxatives fail to provide adequate relief.

Movetis present data on 5-HT4 agonist prucalopride (Resolor)

Prucalopride was found to significantly improve bowel function in patients with chronic constipation. It was found to have a favorable safety profile and was well tolerated.

EPIX 5-HT4 agonist PRX-03140 enters Phase IIb trials

EPIX Pharmaceuticals has initiated a Phase 2b trial of its 5-HT4 agonist PRX-03140 in Alzheimer’s Disease. It will be administered in combination with Aricept.

Alizyme discontinue IBS drug renzapride

Alizyme have decided to discontinue developmet of renzapride following disappointing Phase III trials in Constipation predominant Irritable Bowel Syndrome (IBS-C). The drug showed “limited clinical improvement” compared with those in the placebo group and “the efficacy shown is not sufficient to justify further development”.